← Back to Search

Monoclonal Antibodies

HZN-1116 for Sjogren's Syndrome

Phase 2
Recruiting
Research Sponsored by Amgen
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Positive for anti-Ro autoantibodies, rheumatoid factor (RF) at screening, or both at screening
Be older than 18 years old
Must not have
Individuals who have had previous treatment with any biologic B cell-depleting therapy (eg, rituximab, ocrelizumab, inebilizumab, or ofatumumab) within 12 months or other B cell targeting therapy (eg, belimumab) or anti-type I IFN pathway therapy (eg, anifrolumab) < 6 months before randomization
Active infections requiring systemic treatment at the time of screening or through randomization, or history of more than 2 infections requiring intravenous (IV) antibiotics within 12 months prior to screening
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years

Summary

This trial aims to determine how well and how safe HZN-1116 is for people with Sjogren's syndrome.

Who is the study for?
This trial is for individuals with Sjogren's Syndrome, a condition that causes dry eyes and mouth. Participants must meet specific criteria like having certain scores on disease activity and symptom scales (ESSDAI >=5 for Population 1; ESSPRI >=5 and ESSDAI <5 for Population 2) and testing positive for particular autoantibodies or rheumatoid factor.
What is being tested?
The study is testing the effectiveness and safety of HZN-1116 compared to a placebo in treating symptoms of Sjogren's Syndrome. It aims to see if HZN-1116 can improve patients' conditions better than an inactive substance.
What are the potential side effects?
While the side effects of HZN-1116 are not detailed here, common side effects in trials may include reactions at the injection site, headaches, fatigue, nausea, or other immune-related responses.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I tested positive for anti-Ro autoantibodies or rheumatoid factor.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
I haven't had B cell-depleting or targeting therapy, or anti-type I IFN pathway therapy in the last 6-12 months.
Select...
I do not have current infections needing treatment or a history of frequent severe infections.
Select...
I have tested positive or been treated for hepatitis B, C, or HIV.
Select...
I have systemic sclerosis.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Trial Design

8Treatment groups
Experimental Treatment
Placebo Group
Group I: HZN-1116 Dose 4 in Population 2Experimental Treatment1 Intervention
Participants will receive Dose 4 of HZN-1116
Group II: HZN-1116 Dose 3 in Population 2Experimental Treatment1 Intervention
Participants will receive Dose 3 of HZN-1116
Group III: HZN-1116 Dose 2 in Population 2Experimental Treatment1 Intervention
Participants will receive Dose 2 of HZN-1116
Group IV: HZN-1116 Dose 2 in Population 1Experimental Treatment1 Intervention
Participants will receive Dose 2 of HZN-1116
Group V: HZN-1116 Dose 1 in Population 2Experimental Treatment1 Intervention
Participants will receive Dose 1 of HZN-1116
Group VI: HZN-1116 Dose 1 in Population 1Experimental Treatment1 Intervention
Participants will receive Dose 1 of HZN-1116
Group VII: Placebo in Population 1Placebo Group1 Intervention
Participants will receive Placebo matched to HZN-1116
Group VIII: Placebo in Population 2Placebo Group1 Intervention
Participants will receive Placebo matched to HZN-1116

Find a Location

Who is running the clinical trial?

AmgenLead Sponsor
1,429 Previous Clinical Trials
1,384,523 Total Patients Enrolled
3 Trials studying Sjogren's Syndrome
650 Patients Enrolled for Sjogren's Syndrome
Horizon Therapeutics Ireland DACLead Sponsor
20 Previous Clinical Trials
2,130 Total Patients Enrolled
1 Trials studying Sjogren's Syndrome
510 Patients Enrolled for Sjogren's Syndrome
MDStudy DirectorAmgen
969 Previous Clinical Trials
928,851 Total Patients Enrolled
3 Trials studying Sjogren's Syndrome
1,128 Patients Enrolled for Sjogren's Syndrome
~175 spots leftby Jun 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top